GSK To Pay $2.2 Billion To Settle Zantac Cancer Lawsuits Brought by 80,000 Consumers
Zantac settlement must still be approved by individual plaintiffs, but is expected to resolve vast majority of cancer lawsuits filed in state courts.
Zantac settlement must still be approved by individual plaintiffs, but is expected to resolve vast majority of cancer lawsuits filed in state courts.
Drug maker is challenging a lower court ruling, which allows Zantac lawsuits in Delaware to move forward to trial over the increased risk of cancer caused by the recalled heartburn medication.
Nearly 75,000 lawsuits over cancer caused by Zantac can proceed, after Delaware state court judge found that plaintiffs' expert witness testimony was sufficient for a jury to consider the claims
Glaxo first discovered a link between NDMA in Zantac and cancer at least four decades ago, according to the lawsuit filed by the independent testing lab that uncovered the cancer risks associated with the heartburn drug
GlaxoSmithKline reportedly faces the bulk of the remaining Zantac cancer lawsuits, with the first case of more than 70,000 claims currently going before a jury in Chicago.
A Zantac recall in 2019 has led to years of litigation against several different drug makers, over cancer-causing chemicals in the widely used heartburn drug.
Sanofi will pay $100 million to resolve about 4,000 claims over toxic chemicals in the recalled heartburn drug, but tens of thousands of additional Zantac cancer lawsuits remain unsettled, with most pending in Delaware state court.
Deal comes as a Delaware judge is currently weighing whether to accept or reject plaintiffs' expert witness testimony in more than 70,000 other Zantac lawsuits still pending in that state.
Second time in the last month GlaxoSmithKline has reached a Zantac settlement agreement just before a case was set to go before a jury, privately resolving claims that the recalled heartburn drug caused cancer
Although GlaxoSmithKline has agreed to several Zantac settlements payouts in recent months, the drug maker indicates that it plans to continue defending against cancer lawsuits being pursued by former users of Zantac.